Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Buy

Price to Earnings Rating

Sell

Analyst Rating

Strong Buy

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Buy

A

Medpace Holdings, Inc. Common Stock (MEDP)

Services-commercial Physical & Biological Research

https://www.medpace.com

Medpace is a late-stage contract research organization, or CRO, that provides full-service drug development and clinical trial services to small and midsized biotechnology, pharmaceutical, and medical device firms. Medpace also offers ancillary services such as bio-analytical laboratory services and imaging capabilities. The company was founded over 30 years ago, and it has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are principally based in the U.S., but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in February 2014, and it exited Medpace in August 2018.

5375 MEDPACE WAY
CINCINNATI, OH

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

08/11/2016

Market Cap

12,030,403,499

Shares Outstanding

30,680,000

Weighted SO

30,683,436

Total Employees

N/A

Upcoming Earnings

07/22/2024

Similar Tickers

IQV --.--%

NEOG --.--%

ICLR --.--%

QGEN --.--%

WAT --.--%

IDXX --.--%

CRL --.--%

RVTY --.--%

SYNH --.--%

Beta

1.3560

Last Div

0.0000

Range

227.21-459.77

Chg

3.7450

Avg Vol

250282

Mkt Cap

12030403499

Exch

NASDAQ

Country

US

Phone

513 579 9911

DCF Diff

-51.6763

DCF

439.1413

Div Yield

0.0000

P/S

5.9262

EV Multiple

28.4630

P/FV

15.7489

Div Yield %

0.0000

P/E

35.3919

PEG

1.6107

Payout

0.0000

Current Ratio

0.8786

Quick Ratio

0.8786

Cash Ratio

0.5144

DSO

54.1388

DIO

0.0000

Op Cycle

54.1388

DPO

6.8550

CCC

47.2839

Gross Margin

0.2816

Op Margin

0.1879

Pretax Margin

0.1956

Net Margin

0.1674

Eff Tax Rate

0.1445

ROA

0.1770

ROE

0.5514

ROCE

0.4115

NI/EBT

0.8555

EBT/EBIT

1.0412

EBIT/Rev

0.1879

Debt Ratio

0.0801

D/E

0.2013

LT Debt/Cap

0.1472

Total Debt/Cap

0.1676

Int Coverage

33.0715

CF/Debt

3.5118

Equity Multi

2.5145

Rec Turnover

6.7419

Pay Turnover

53.2461

Inv Turnover

0.0000

FA Turnover

7.9177

Asset Turnover

1.0573

OCF/Share

17.4203

FCF/Share

16.2245

Cash/Share

16.4858

OCF/Sales

0.2659

FCF/OCF

0.9314

CF Coverage

3.5118

ST Coverage

24.6183

CapEx Coverage

14.5682

Div&CapEx Cov

14.5682

P/BV

15.7489

P/B

15.7489

P/S

5.9262

P/E

35.3919

P/FCF

23.9270

P/OCF

22.2761

P/CF

22.2761

PEG

1.6107

P/S

5.9262

EV Multiple

28.4630

P/FV

15.7489

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Nov 01, 23:33 Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Medpace Holdings, Inc. for potential violations of securities laws GlobeNewswire Inc. Oct 25, 00:36 NASDAQ: MEDP Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Medpace Holdings, Inc. (NASDAQ: MEDP) Investors with Significant Losses to Contact the Firm GlobeNewswire Inc. Aug 03, 01:00 MEDPACE ALERT: Bragar Eagel & Squire, P.C. is Investigating Medpace Holdings, Inc. on Behalf of Medpace Stockholders and Encourages Investors to Contact the Firm GlobeNewswire Inc. Aug 02, 23:46 Medpace Holdings (MEDP) Reveals “Shocking” Bookings Miss, Shares Fall - Hagens Berman Zacks Investment Research Dec 26, 12:20 Tenet Healthcare (THC) Gains 60% in a Year: More Room to Run? Zacks Investment Research Dec 26, 12:20 Tenet Healthcare (THC) Gains 60% in a Year: More Room to Run? The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad The Motley Fool Nov 11, 10:38 Stock Buybacks: The Good and the Bad

Revenue Product Segmentation